Lumos Diagnostics FebriDx® rollout expands to 141 WellStreet urgent care locations
Lumos Diagnostics (ASX: LDX) received confirmation on 9 November 2026 that WellStreet Urgent Care will expand standardized adoption of its FebriDx® test to a total of 141 locations across Ohio, Georgia and Michigan. WellStreet is described in the announcement as the 6th largest urgent care network in the U.S.
The headline points from the announcement:
- Testing rolls out to an additional 97 locations.
- The network represents over 1 million acute respiratory presentations per annum.
- Upon implementation, the number of U.S. sites using FebriDx® reaches 365.
Lumos and WellStreet anticipate that expansion will continue to all WellStreet locations (200+) in all markets by 31 December 2026.
For investors, the update shows a product moving from a single site pilot to a network-wide protocol.
When big ASX news breaks, our subscribers know first
From single site pilot to network standard
The path to the current rollout has been staged, with each step following the one before it. The CLIA waiver and the pilot’s success preceded each step up in locations.
The CLIA waiver reclassified FebriDx from a moderate-complexity laboratory test to one usable at any Certificate of Waiver site, a pool of more than 300,000 US locations that includes primary care offices and retail pharmacies as well as urgent care.
- 16 October 2025: Lumos announced a single site pilot agreement with WellStreet, through WellStreet’s joint venture with Piedmont Healthcare in Atlanta, Georgia, to advance testing and reimbursement pathways.
- 27 March 2026: The U.S. Food and Drug Administration (U.S. FDA) granted CLIA waiver for FebriDx®.
- 14 April 2026: WellStreet and Lumos announced expansion to an additional 43 locations in Michigan and Georgia.
- 9 November 2026: WellStreet elected to expand to a total of 141 locations across Ohio, Georgia and Michigan.
How WellStreet’s protocol puts FebriDx® at the point of care
Under a protocol implemented by WellStreet, FebriDx® will be offered to patients presenting with acute respiratory infection (ARI) symptoms. Test results will be available to the provider before entering the examination room, enabling faster clinical decision-making and more timely diagnosis and treatment.
WellStreet estimates that ARI symptoms account for 70-80% of patient visits during cold and flu season.
What FebriDx® does
FebriDx® is a rapid point-of-care test that uses a fingerstick blood sample to aid in the differentiation between bacterial and non-bacterial infection. Knowing which type of infection is involved helps clinicians decide whether antibiotics are appropriate, which is the focus of antibiotic stewardship.
Brian S. Bobb, M.D., Senior Medical Officer, WellStreet Urgent Care
“…Along with patient and clinician satisfaction, we have seen measurable improvement in antibiotic stewardship that can be attributed to the introduction of this test in our centers…”
Doug Ward, CEO, Lumos Diagnostics
“The decision by WellStreet, one of the leading urgent care operators in the U.S., to standardise FebriDx® within its triage protocols across additional locations is a strong endorsement of the product’s clinical value…”
What happens next for Lumos and WellStreet
The announcement points to two forward steps:
- Rollout to the additional locations, bringing U.S. sites using FebriDx® to 365 upon implementation. Dr Bobb said expanded access is expected “in the coming weeks”.
- Expansion anticipated to include all WellStreet locations (200+) in all markets by 31 December 2026.
The WellStreet network represents over 1 million acute respiratory presentations per annum, and it is standardizing FebriDx® within its triage protocols.
Commercial traction depends on payment as much as clinical uptake, and early claims data showed reimbursement above the Medicare benchmark of US$41.38 per test on more than 90% of submitted claims.
Don’t Miss the Next Healthcare Breakout
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis and the full announcement. Join 20,000+ subscribers who stay ahead of the market. Click the “Free Alerts” button at Big News Blast to receive alerts the moment news breaks.